• Something wrong with this record ?

Serum levels of selected cytokines and soluble adhesion molecules in acute myeloid leukemia: Soluble receptor for interleukin-2 predicts overall survival

T. Kupsa, J. Vanek, P. Zak, L. Jebavy, JM. Horacek

. 2020 ; 128 (-) : 155005. [pub] 20200130

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

BACKGROUND: Acute myeloid leukemia (AML) cells are highly resistant to chemotherapeutic drugs. Cytokines and adhesion molecules may contribute to this resistance and affect treatment outcome. The aim of this study was to evaluate the independence and additional prognostic information of baseline serum levels of selected cytokines and soluble adhesion molecules, included in analyses with standard prognostic indicators. METHODS: We used biochip array technology to measure levels of selected cytokines and soluble adhesion molecules in serum samples of 80 newly diagnosed AML patients. The markers of tumour microenvironment were analysed against high risk karyotype, hyperleucocytosis, higher age, lactic dehydrogenase levels and presence of FLT3-ITD and NPM-1 mutation. RESULTS: All evaluated analytes were independent of standard prognostic indicators. Fifteen were associated with overall and eight with progression-free survival in univariate analysis. After correction for multiple testing, we identified soluble interleukin-2 receptor-α as an independent indicator of overall survival. Further, the soluble type I TNF-α receptor was close to statistical significance for both overall and progression-free survival. CONCLUSIONS: Baseline levels of soluble interleukin-2 receptor-α predict overall survival in newly diagnosed AML. The TNF-α type I soluble receptor is a candidate prognostic marker in AML and is worth of further investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026732
003      
CZ-PrNML
005      
20220103142734.0
007      
ta
008      
211013s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cyto.2020.155005 $2 doi
035    __
$a (PubMed)32006876
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kupsa, Tomáš $u Department of Military Internal Medicine and Military Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), Hradec Kralove, Czech Republic; Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove, Czech Republic $7 xx0267991
245    10
$a Serum levels of selected cytokines and soluble adhesion molecules in acute myeloid leukemia: Soluble receptor for interleukin-2 predicts overall survival / $c T. Kupsa, J. Vanek, P. Zak, L. Jebavy, JM. Horacek
520    9_
$a BACKGROUND: Acute myeloid leukemia (AML) cells are highly resistant to chemotherapeutic drugs. Cytokines and adhesion molecules may contribute to this resistance and affect treatment outcome. The aim of this study was to evaluate the independence and additional prognostic information of baseline serum levels of selected cytokines and soluble adhesion molecules, included in analyses with standard prognostic indicators. METHODS: We used biochip array technology to measure levels of selected cytokines and soluble adhesion molecules in serum samples of 80 newly diagnosed AML patients. The markers of tumour microenvironment were analysed against high risk karyotype, hyperleucocytosis, higher age, lactic dehydrogenase levels and presence of FLT3-ITD and NPM-1 mutation. RESULTS: All evaluated analytes were independent of standard prognostic indicators. Fifteen were associated with overall and eight with progression-free survival in univariate analysis. After correction for multiple testing, we identified soluble interleukin-2 receptor-α as an independent indicator of overall survival. Further, the soluble type I TNF-α receptor was close to statistical significance for both overall and progression-free survival. CONCLUSIONS: Baseline levels of soluble interleukin-2 receptor-α predict overall survival in newly diagnosed AML. The TNF-α type I soluble receptor is a candidate prognostic marker in AML and is worth of further investigation.
650    _2
$a molekuly buněčné adheze $x krev $7 D015815
650    _2
$a cytokiny $x krev $7 D016207
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-2 $x krev $x genetika $7 D007376
650    _2
$a akutní myeloidní leukemie $x krev $x genetika $x mortalita $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a nádorové mikroprostředí $x fyziologie $7 D059016
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vanek, Jan $u Department of Military Internal Medicine and Military Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), Hradec Kralove, Czech Republic
700    1_
$a Zak, Pavel $u Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Jebavy, Ladislav $u Department of Military Internal Medicine and Military Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), Hradec Kralove, Czech Republic; Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove, Czech Republic
700    1_
$a Horacek, Jan M $u Department of Military Internal Medicine and Military Hygiene, University of Defence, Faculty of Military Health Sciences (FMHS), Hradec Kralove, Czech Republic; Department of Internal Medicine IV - Hematology, University Hospital Hradec Kralove, Czech Republic. Electronic address: jan.horacek@unob.cz
773    0_
$w MED00001313 $t Cytokine $x 1096-0023 $g Roč. 128, č. - (2020), s. 155005
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32006876 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20220103142733 $b ABA008
999    __
$a ok $b bmc $g 1715468 $s 1147239
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 128 $c - $d 155005 $e 20200130 $i 1096-0023 $m Cytokine (Philadelphia, Pa. Print) $n Cytokine $x MED00001313
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...